Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation?

Literature DB >> 23129871

Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation?

Abstract

Entities: Chemical Disease Gene

Year: 2012 PMID： 23129871 PMCID： PMC3477840 DOI： 10.4212/cjhp.v65i5.1180

Source DB: PubMed Journal: Can J Hosp Pharm ISSN： 0008-4123

× No keyword cloud information.

24 in total

1. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

Authors: Yu Chen Barrett; Zhaoqing Wang; Charles Frost; Andrew Shenker
Journal: Thromb Haemost Date: 2010-10-26 Impact factor: 5.249

2. Determination of rivaroxaban in human plasma samples.

Authors: Job Harenberg; Sandra Erdle; Svetlana Marx; Roland Krämer
Journal: Semin Thromb Hemost Date: 2012-02-17 Impact factor: 4.180

Review 3. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Authors: Scott Kaatz; Peter A Kouides; David A Garcia; Alex C Spyropolous; Mark Crowther; Jim D Douketis; Anthony K C Chan; Andra James; Stephan Moll; Thomas L Ortel; Elizabeth M Van Cott; Jack Ansell
Journal: Am J Hematol Date: 2012-04-04 Impact factor: 10.047

4. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Authors: John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf
Journal: Circulation Date: 2011-05-16 Impact factor: 29.690

Review 5. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors: Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal: Thromb Haemost Date: 2010-03-29 Impact factor: 5.249

Review 6. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.

Authors: Ken Uchino; Adrian V Hernandez
Journal: Arch Intern Med Date: 2012-01-09

Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation?

1. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

2. Determination of rivaroxaban in human plasma samples.

Review 3. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

4. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Review 5. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Review 6. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.

Review 7. Human recombinant activated protein C for severe sepsis.

8. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

9. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated.

10. Why most published research findings are false.

1. Optimal warfarin management can be achieved in all practice settings.